Table 3.
Some representative clinical trials evaluating efficacy of microbiota modulation and probiotics in COVID-19
| Country | Study type (Trial number) | Evaluation goals | Intervention/Treatment |
|---|---|---|---|
| Canada | Randomised, single-blinded trial with 23 participants (NCT04458519) | Evaluation of intranasal probiotic administration for reduction of COVID-19 symptoms severity. | Probiorinse (2.4 Billion CFU (Colony-Forming Units) of Lactococcus Lactis W136, (NPN: 80085895)) |
| USA | open-label, randomized, and controlled clinical trial with 100 participants (NCT04540406) | Evaluation of NBT-NM108 as an early treatment by modulating gut microbiota in COVID-19. | NBT-NM108, a novel botanical based fixed combination drug |
| Mexico | Interventional, randomized, single-blind trial with 240 participants (NCT04507867) | Evaluation of nutritional support system (NSS) in COVID-19 patients with co-morbidities and reduction of complications. | NSS with Saccharomyces bourllardii |
| Argentina | Randomized, triple blind trial with 140 participants (NCT04403646) | Evaluation of Tannin specific natural extract for COVID-19 due to their anti-inflammatory, anti-oxidative and intestinal microbiota modulatory activity. | Dry extract of polyphenols (tannins) from quebracho and chestnut |
| Spain | Randomized, open label trial with 41 participants (NCT04390477) | Evaluation of probiotics in COVID-19 patients for improvement of symptoms and reduction of hospital stay. | Probiotic strain with maltodextrin as excipient |
| Spain | Randomized, Quadruple blind trial with 314 participants (NCT04366180) | Evaluation of Lactobacillus coryniformis K8 on the incidence and severity of Covid-19 in health workers exposed to virus. | Lactobacillus K8 per day (3×10^9 cfu/day) |
| Mexico | Randomized, quadruple blind trial with 300 participants (NCT04517422) | Evaluation of efficacy of L. plantarum and P. acidilactici in Adults With SARS-CoV-2. | Combination of Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and Pediococcus acidilactici CECT7483 |
| Italy | Randomized, single blind trial with 152 participants (NCT04366089) | Evaluation of oxygen ozone and probiotics as an adjuvant strategy for management of COVID-19 and modulation of microbiota. | Oxygen-ozone therapy with dietary supplements SivoMixx (Streptococcus thermophilus DSM322245, Bifidobacterium lactis DSM32246, Bifidobacterium lactis DSM32247, Lactobacillus acidophilus DSM32241, Lactobacillus helveticus DSM32242, Lactobacillus paracasei DSM32243, Lactobacillus plantarum DSM32244, Lactobacillus brevis DSM27961) |
| USA | Randomized, triple blind trial with 182 participants (NCT04399252) | Evaluation of the effect of probiotic Lactobacillus rhamnosus GG (LGG) and COVID-19 on the microbiome in exposed household contacts. | Lactobacillus rhamnosus GG |